CaMK4 compromises podocyte function in autoimmune and nonautoimmune kidney disease

Area of Science:

• Nephrology
• Molecular Biology
• Cell Biology

Background:

• Podocyte injury is central to various kidney diseases, including autoimmune and nonautoimmune conditions.
• Calcium signaling pathways are implicated in podocyte damage, but the specific role of Ca2+/calmodulin-dependent kinase (CaMK) signaling remains unclear.

Purpose of the Study:

• To investigate the role of CaMK signaling, specifically CaMK4, in podocyte injury.
• To explore CaMK4 as a potential therapeutic target for kidney diseases involving podocyte damage.

Main Methods:

• Assessed CaMK expression in podocytes from patients with lupus nephritis and focal segmental glomerulosclerosis, and in mouse models of kidney injury.
• Utilized CaMK4 inhibitors delivered specifically to podocytes in lupus-prone, lipopolysaccharide-induced, and adriamycin-induced kidney injury models.
• Examined effects on podocyte ultrastructure, immune complex deposition, crescent formation, proteinuria, and expression of key podocyte markers (nephrin, synaptopodin).

Main Results:

• CaMK4 expression was elevated in podocytes from patients and mice with kidney disease.
• CaMK4 modulated podocyte motility, suppressed nephrin and synaptopodin expression, and promoted synaptopodin degradation via 14-3-3β phosphorylation.
• Targeted inhibition of CaMK4 preserved podocyte structure, reduced proteinuria, and ameliorated kidney disease in various experimental models.

Conclusions:

• CaMK4 plays a critical role in both immune and non-immune mediated podocyte injury.
• Targeted, cell-specific inhibition of CaMK4 demonstrates therapeutic potential for lupus nephritis and other podocytopathies, including focal segmental glomerulosclerosis.